Designed Peptide Inhibitors of STEP Phosphatase–GluA2 AMPA Receptor Interaction Enhance the Cognitive Performance in Rats

Author(s):  
Horea Stefan Szedlacsek ◽  
Dávid Bajusz ◽  
Rodica Aura Badea ◽  
Andreea Pop ◽  
Constantin Cătălin Bică ◽  
...  
2010 ◽  
Vol 56 (8) ◽  
pp. 962-970 ◽  
Author(s):  
Xin Shao ◽  
Lijun Zhu ◽  
Yubin Wang ◽  
Yuting Lu ◽  
Wenhai Wang ◽  
...  

2020 ◽  
Vol 63 (22) ◽  
pp. 13709-13718
Author(s):  
Timothy Lynagh ◽  
Stephan Kiontke ◽  
Maria Meyhoff-Madsen ◽  
Bengt H. Gless ◽  
Jónas Johannesen ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Vasiliy V. Reshetnikov ◽  
Polina E. Kisaretova ◽  
Nikita I. Ershov ◽  
Anastasia S. Shulyupova ◽  
Dmitry Yu. Oshchepkov ◽  
...  

AbstractLearning and memory are among higher-order cognitive functions that are based on numerous molecular processes including changes in the expression of genes. To identify genes associated with learning and memory formation, here, we used the RNA-seq (high-throughput mRNA sequencing) technology to compare hippocampal transcriptomes between mice with high and low Morris water maze (MWM) cognitive performance. We identified 88 differentially expressed genes (DEGs) and 24 differentially alternatively spliced transcripts between the high- and low-MWM-performance mice. Although the sets of DEGs and differentially alternatively spliced transcripts did not overlap, both were found to be enriched with genes related to the same type of biological processes: trans-synaptic signaling, cognition, and glutamatergic transmission. These findings were supported by the results of weighted-gene co-expression network analysis (WGCNA) revealing the enrichment of MWM-cognitive-performance-correlating gene modules with very similar Gene Ontology terms. High-MWM-performance mice manifested mostly higher expression of the genes associated with glutamatergic transmission and long-term potentiation implementation, which are processes necessary for memory acquisition and consolidation. In this set, there were genes participating in the regulation of trans-synaptic signaling, primarily AMPA receptor signaling (Nrn1, Nptx1, Homer3, Prkce, Napa, Camk2b, Syt7, and Nrgn) and calcium turnover (Hpca, Caln1, Orai2, Cpne4, and Cpne9). In high-MWM-performance mice, we also demonstrated significant upregulation of the “flip” splice variant of Gria1 and Gria2 transcripts encoding subunits of AMPA receptor. Altogether, our data helped to identify specific genes in the hippocampus that are associated with learning and long-term memory. We hypothesized that the differences in MWM cognitive performance between the mouse groups are linked with increased long-term potentiation, which is mainly mediated by increased glutamatergic transmission, primarily AMPA receptor signaling.


2004 ◽  
Vol 76 (5) ◽  
pp. 921-930
Author(s):  
T. N. Johansen ◽  
J. R. Greenwood ◽  
S. B. Vogensen ◽  
Povl Krogsgaard-Larsen

(S)-Glutamic acid (Glu), the major excitatory neurotransmitter in the central nervous system, operates through ionotropic as well as metabotropic receptors and is considered to be involved in a number of degenerative brain diseases that are currently without any satisfactory therapeutic treatment. Until recently, development of selective Glu receptor agonists had mainly been based on structural optimization of naturally occurring lead compounds structurally related to Glu. Crystallization of the agonist binding domain of the GluR2 subunit of the 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptor subtype of ionotropic Glu receptors (iGluRs) in the presence or absence of an agonist has provided important information about ligand-receptor interaction mechanisms. The availability of such binding domain crystal structures has formed the basis for rational design of ligands, especially for the AMPA subtypes of iGluRs.


2021 ◽  
Author(s):  
Yixue Li ◽  
Hengrui Liu ◽  
Yue Han

Abstract Background The diagnosis and prognosis of neck squamous cell carcinoma (HNSC) is a challenge for clinical HNSC management, thus, the investigation of molecular biomarkers of HNSC is urgent. We hypothesized that Cornichon Family AMPA Receptor Auxiliary Protein 4 (CNIH4) is a biomarker for HNSC.Methods We analyzed mRNA seq data, protein staining data, and single-cell expression data of HNSC from open databases and evaluated the diagnostic and prognostic value of CNIH4, and investigated the association of CNIH4 to HNSC cancer biology and immunity.Results CNIH4 was expressed higher and have higher copy number in HNSC compared to normal tissues. CNIH4 was associated with worse overall survival of HNSC patients. A survival nomogram was constructed. 2012 and 421genes were identified as positively and negatively associated with CNIH4 respectively, and they were enriched in “Cell cycle”, “DNA replicate”, “Cytokine−cytokine receptor interaction”, etc. CNIH4 was positively correlated with “stemness”, “cell cycle”, and “DNA repair” in single-cell data. CNIH4 was potentially associated with changes in multiple immune cell infiltration and cancer immune escape. Conclusion CNIH4 is a diagnostic and prognostic biomarker for HNSC patients and can potentially affect the cancer stemness and tumor immune microenvironment of HNSC cells.


2019 ◽  
Vol 34 (1) ◽  
pp. 93-102
Author(s):  
Simon E Ward ◽  
Mark H Harries ◽  
Laura Aldegheri ◽  
Andrea M Bradford ◽  
Elisa Ballini ◽  
...  

Purpose: There is considerable interest in positive allosteric modulators (PAMs) of the α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) subtype of ionotropic glutamate receptors as therapeutic agents for a range of cognitive and mood disorders. However, the challenge is to increase AMPA receptor (AMPAR) function sufficient to enhance cognitive function but not to the extent that there are mechanism-related pro-convulsant or convulsant side effects. In this present study, we report the preclinical pharmacology data for MDI-222, an AMPAR PAM which enhances cognition but has a much reduced side-effect (i.e. convulsant) liability relative to other molecules of this mechanism. Methods: The pharmacological effects of MDI-222 were characterised in in vitro and in vivo preclinical electrophysiology, efficacy (cognition), side-effect (pro-convulsant/convulsant), tolerability and toxicity assays. Results: We demonstrate that MDI-222 is an AMPAR PAM, since it enhanced AMPAR function in vitro at human (hGluA1-4) and rat (rGluA2) homomeric receptors, and potentiated hetero-oligomeric AMPARs in rat neurons. MDI-222 enhanced electrically evoked AMPAR-mediated synaptic transmission in the anaesthetised rat at 10 mg/kg (administered intravenously) and did not significantly lower the seizure threshold in the pro-convulsant maximal electroshock threshold test (MEST) at any dose tested up to a maximum of 30 mg/kg (administered by oral gavage (p.o.)). MDI-222 reversed a delay-induced deficit in novel object recognition (NOR) in rats with a minimum effective dose (MED) of 0.3 mg/kg (p.o.) following acute administration, which was reduced to 0.1 mg/kg following sub-chronic administration, and improved passive avoidance performance in scopolamine-impaired rats with a MED of 10 mg/kg p.o. On the other hand, MDI-222 was not pro-convulsant in the MEST, resulting in a therapeutic window between plasma concentrations that enhanced cognitive performance and those associated with mechanism-related side effects of ⩾1000-fold. Unfortunately, despite the excellent preclinical profile of this compound, further development had to be halted due to non-mechanism-related issues. Conclusions: We conclude that MDI-222 is an AMPAR PAM which enhances cognitive performance in rats and has a significantly improved safety profile in preclinical species.


2008 ◽  
Vol 72 (2) ◽  
pp. 133-139 ◽  
Author(s):  
Angeliki Buku ◽  
Inna Keselman ◽  
Dmitry Lupyan ◽  
Mihaly Mezei ◽  
Joseph A. Price

2007 ◽  
Vol 3 (10) ◽  
pp. 2
Author(s):  
ELIZABETH MECHCATIE

GeroPsych ◽  
2011 ◽  
Vol 24 (2) ◽  
pp. 83-92 ◽  
Author(s):  
Valentina A. Tesky ◽  
Christian Thiel ◽  
Winfried Banzer ◽  
Johannes Pantel

To investigate the effects of leisure activities on cognitive performance of healthy older subjects, an innovative intervention program was developed. Frequent participation in cognitively stimulating activities (i.e., reading, playing chess, or playing music) is associated with reduced risk of dementia. AKTIVA (active cognitive stimulation – prevention in the elderly) is an intervention program designed to enhance cognitive stimulation in everyday life by increasing cognitive stimulating leisure activities. The present study determines the effects of AKTIVA on cognitive function, mood and attitude toward aging in a sample of older participants from the general population. Several measurement instruments were used including the Alzheimer’s Disease Assessment Scale (ADAS-Cog), the Trail-Making Test (TMT), and the Memory Complaint Questionnaire (MAC-Q). Initially, the sample consisted of 307 older persons (170 female, 72 ± 7 years). The intervention was evaluated with a randomized, controlled pre-post follow-up design. Participants were randomly assigned to one of three conditions: AKTIVA intervention (n = 126), AKTIVA intervention plus nutrition and exercise counseling (n = 84), no-intervention control group (n = 97). The AKTIVA intervention consisted of 8 weekly sessions and two booster sessions after a break of 4 months. Participation in the group program resulted in positive effects on cognitive function and attitude toward aging for subassembly groups. Older persons (≥ 75 years) showed enhanced speed of information processing (by TMT Version A) (F = 4.17*, p < .05); younger participants (< 75 years) showed an improvement in subjective memory decline (by MAC-Q) (F = 2.55*, p < .05). Additionally, AKTIVA enhanced the frequency of activities for leisure activities for subassembly groups. The results of this study suggest that the AKTIVA program can be used to increase cognitively stimulating leisure activities in the elderly. Further research is necessary to identify the long-term effects of this intervention particularly with respect to the prevention of dementia.


Sign in / Sign up

Export Citation Format

Share Document